FRLN 6.48 (+0%)
US35655L1070BiotechnologyBiotechnology

Freeline Therapeutics Holdings (FRLN) Stock Highlights

6.48 | +0%
2024-12-21 07:28:43
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.

Statistics

Range Today
6.48 6.48
Volume Today 0
Range 1 Year
2.11 8.7
Volume 1 Year 45.41M
Range 3 Year
2.11 240
Volume 3 Year 53.47M
Range 10 Year
2.11 325.35
Volume 10 Year 54.08M

Highlights

Market Capitalization 28.24M (micro)
Floating Shares 26.8M
Current Price 6.48
Price To Earnings -0.57
Price To Revenue 640.08
Price To Book 0.94
Earnings Per Share -11.4
Payout Ratio 0%

Performance

Latest 0%
1 Month +1.41%
3 Months +2.69%
6 Months +74.66%
1 Year -14.62%
3 Years -97.08%
5 Years -97.66%
10 Years -97.66%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.